{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:12:21Z","timestamp":1775067141250,"version":"3.50.1"},"reference-count":73,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2016,4,12]]},"DOI":"10.1517\/14656566.2016.1159296","type":"journal-article","created":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T17:27:21Z","timestamp":1456507641000},"page":"861-870","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer\u2019s disease"],"prefix":"10.1517","volume":"17","author":[{"given":"Rachel A.","family":"Nieto","sequence":"first","affiliation":[{"name":",","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William James","family":"Deardorff","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George T.","family":"Grossberg","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,3,30]]},"reference":[{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.11.007"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61682-2"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60692-4"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1305541"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510370044030"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80127-6"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0038-9"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720509787313961"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2005.08.039"},{"key":"e_1_3_2_14_1","first-page":"2","article-title":"A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer\u2019s disease","volume":"15","author":"Nordberg A","year":"2013","unstructured":"Nordberg A, Ballard C, Bullock R, et al. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer\u2019s disease. Prim Care Companion CNS Disord. 2013;15:2.","journal-title":"Prim Care Companion CNS Disord"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199912040-00005"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02052.x"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000281845.40390.8b"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100242"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007312154"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X253438"},{"key":"e_1_3_2_21_1","unstructured":"Exelon Patch. (rivastigmine) [package insert]. East Hanover: Novartis Pharmaceutical Corporation. Revised February 2015. https:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/exelonpatch.pdf. Accessed 14 November 2015."},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200115050-00004"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006297748"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1788"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000281847.17519.e0"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199700112-00004"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000296073"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1998.tb02542.x"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200624030-00006"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/geront\/gnq050"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2007.01307.x"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/1533317510391240"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2534"},{"key":"e_1_3_2_34_1","unstructured":"US Food and Drug Administration. Drug Approval Package. Exelon Patch (rivastigmine transdermal system). 2007 [cited 2015 November 18]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022083_exelon_toc.cfm"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02641.x"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1159\/000340056"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4080"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-014-0088-8"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1058"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12158"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.513849"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/1533317515603687"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.2174\/1567205011666141218122835"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12385"},{"key":"e_1_3_2_45_1","doi-asserted-by":"crossref","unstructured":"Grossberg G Meng X Velting D A 24-week randomized controlled trial of 13.3 mg\/24 h versus 4.6 mg\/24 h rivastigmine patch in patients with severe Alzheimer\u2019s disease: analysis of neuropsychiatric inventory items. Abstract ID: 4325 Alzheimer\u2019s Association International Conference; 18\u201323 July 2015; Washington DC.","DOI":"10.1016\/j.jalz.2015.06.320"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.802230"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041470"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20700"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000010"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e31818b1c2c"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0000000000000073"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12621"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-009-0075-9"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.43"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03450.x"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13511"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488612800492717"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2010.05.024"},{"key":"e_1_3_2_59_1","unstructured":"Important Drug Warning. In: U.S. Food and Drug Administration. 2010 [cited 2015 Nov 19]. http:\/\/www.fda.gov\/downloads\/Safety\/MedWatch\/SafetyInformation\/UCM226090.pdf."},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144337"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1806"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1159\/000381894"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12374"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1159\/000345989"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1586\/ern.11.178"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02253.x"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1177\/1533317509333037"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.582484"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02713.x"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730100-00007"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.06.019"},{"key":"e_1_3_2_72_1","unstructured":"Medical review(s). In: FDA Drug Approval Package. 2010 [cited 2015 Nov 19]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022568Orig1s000MedR.pdf"},{"key":"e_1_3_2_73_1","unstructured":"Summary review. In: FDA Drug Approval Package. 2010 [cited 2015 Nov 19]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022568Orig1s000SumR.pdf"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4247"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.2174\/1567205011666140618102224"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S93937"},{"key":"e_1_3_2_77_1","unstructured":"Corium Initiates Phase 1 Clinical Trial of Corplex(TM) Donepezil Transdermal System for the Treatment of Alzheimer\u2019s Disease. GlobalNewsWire. [cited 2015 Nov 19]. http:\/\/globenewswire.com\/news-release\/2015\/08\/25\/763182\/10147056\/en\/Corium-Initiates-Phase-1-Clinical-Trial-of-Corplex-TM-Donepezil-Transdermal-System-for-the-Treatment-of-Alzheimer-s-Disease.html"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14656566.2016.1159296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T22:45:14Z","timestamp":1770936314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14656566.2016.1159296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,30]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,4,12]]}},"alternative-id":["10.1517\/14656566.2016.1159296"],"URL":"https:\/\/doi.org\/10.1517\/14656566.2016.1159296","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}